Research suggests Celebrex risk lower than Vioxx

Share this article:
Celebrex appears to not carry the same heart risk as Merck's Vioxx, according to new research published this week in the medical journal Annals of Internal Medicine.
Researchers at the University of Pennsylvania found that Vioxx was 2.72 times as likely to be associated with a nonfatal first heart attack than Celebrex -- contradicting the claims of some scientists that all cox-2 medicines may carry similar dangers.
"What that implies is that all cox-2 inhibitors may not be the same," Stephen Kimmel, associate professor of medicine and epidemiology and lead author of the study, told the Associated Press.
However, University of Pennsylvania cardiologist and pharmacologist, Garret Fitzgerald, questioned whether the study proved anything new.
"It's not a clean bill of health for Celebrex," Fitzgerald said in an Associated Press report. "It's well recognized that these types of studies are not conclusive."
To find proof, Fitzgerald said, researchers would have to conduct a random study involving people who took Vioxx, people who took Celebrex and people who took placebo – all before they had heart attacks.   
Instead, researchers studied 1,718 patients in the Philadelphia area who had heart attacks and who were treated at one of 36 hospitals, and a comparison group of 6,800 people in the region.
The study was co-funded by Pfizer, Merck and the federal government.
Vioxx was withdrawn from the market on Sept. 30 after a study revealed the risk of heart attacks and stroke was doubled when the drug was taken for more than 18 months.
According to data from IMS Health, in October, sales of Celebrex topped $260 million – 63.5 percent of the market for cox-2 inhibitors.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?